TAZAROTENE
Drug
Sandoz Inc.
Total Payments
$3.4M
Transactions
53
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $3.4M | 53 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.4M | 53 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING TAZAROTENE CREAM 0.1% TO TAZORAC? (TAZAROTENE) CREAM 0.1% AND BOTH ACTIVE TREATMENTS TO A VEHICLE CONTROL IN THE TREATMENT OF ACNE VULGARIS | Sandoz Inc. | $1.9M | 0 |
| A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING TAZAROTENE CREAM 0.05% TO TAZORAC? (TAZAROTENE) CREAM 0.05% AND BOTH ACTIVE TREATMENTS TO A VEHICLE CONTROL IN THE TREATMENT OF STABLE PLAQUE PSORIASIS | Sandoz Inc. | $1.4M | 0 |
| A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING TAZAROTENE CREAM 0.05% TO TAZORAC (TAZAROTENE) CREAM 0.05% AND BOTH ACTIVE TREATMENTS TO A VEHICLE CONTROL IN THE TREATMENT OF STABLE PLAQUE PSORIASIS | Sandoz Inc. | $29,000 | 0 |
Top Doctors Receiving Payments for TAZAROTENE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New Albany, IN | $3.4M | 53 |
Ad
Manufacturing Companies
- Sandoz Inc. $3.4M
Product Information
- Type Drug
- Total Payments $3.4M
- Total Doctors 0
- Transactions 53
About TAZAROTENE
TAZAROTENE is a drug associated with $3.4M in payments to 0 healthcare providers, recorded across 53 transactions in the CMS Open Payments database. The primary manufacturer is Sandoz Inc..
Payment data is available from 2017 to 2017. In 2017, $3.4M was paid across 53 transactions to 0 doctors.
The most common payment nature for TAZAROTENE is "Unspecified" ($3.4M, 100.0% of total).
TAZAROTENE is associated with 3 research studies, including "A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING TAZAROTENE CREAM 0.1% TO TAZORAC? (TAZAROTENE) CREAM 0.1% AND BOTH ACTIVE TREATMENTS TO A VEHICLE CONTROL IN THE TREATMENT OF ACNE VULGARIS" ($1.9M).